Friedreich’s ataxia (FA) is associated with progressive cardiac hypertrophy resulting from a genetic abnormality in the frataxin
gene. Cardiac involvement is the most common cause of death (59%) in FA patients. Cardiac related death occurs at a significantly
younger age than non-cardiac related death. Idebenone is a short-chain quinone analogue with a potent free-radical scavenger action. This
drug has the potential to preserve and even improve mitochondrial function.Studies on Idebenone treatment showed rather conflicting results
on FA cardiomyopathy. The present article reviews the clinical features of FA cardiomyopathy, imaging techniques used to diagnose,
follow and monitor therapy which aimed to revert FA cardiomyopathy.